Tags

Type your tag names separated by a space and hit enter

[Retinal regeneration with iPS cells ‒ Clinical trials for retinal degenerative disorders].
Nihon Rinsho Meneki Gakkai Kaishi. 2015; 38(2):79-85.NR

Abstract

Potential for re-programming cells has become widely accepted as a tool for obtaining transplantation materials. There has been great interest in cell-based therapies, including retinal transplants, because there is a reduced risk of immune rejection. Stem cells have the capacity for self-renewal plus the capacity to generate several differentiated cells. They are derived from many sources including human adult-derived induced pluripotent stem (iPS) cells and have found early application in the context of ocular disease. In results, our established iPS-retinal pigment epithelial (RPE) cells are high-quality RPE cells. iPS cells-derived RPE cells clearly showed polygonal morphology (mostly hexagonal) and contained melanin. Moreover, RPE cells derived from iPS cells had many characteristics of mature RPE cells in vivo, but no characteristics of pluripotent stem cells. Recently, we transplanted RPE cell sheets to treat a patient with wet age-related macular degeneration (September, 2014). In addition, we are now conducting experiments to determine whether allogeneic T cells can recognize iPS-RPE cells from HLA-A, B, DRB1 locus homozygote donors. iPS bank might be useful as allografts in retinal disorders, if the recipient T cells cannot respond to allogeneic RPE cells because of match to some of main HLA antigens.

Authors+Show Affiliations

Laboratory for Retinal Regeneration, Center for Developmental Biology, RIKEN.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

26016634

Citation

Sugita, Sunao. "[Retinal Regeneration With iPS Cells ‒ Clinical Trials for Retinal Degenerative Disorders]." Nihon Rinsho Men'eki Gakkai Kaishi = Japanese Journal of Clinical Immunology, vol. 38, no. 2, 2015, pp. 79-85.
Sugita S. [Retinal regeneration with iPS cells ‒ Clinical trials for retinal degenerative disorders]. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(2):79-85.
Sugita, S. (2015). [Retinal regeneration with iPS cells ‒ Clinical trials for retinal degenerative disorders]. Nihon Rinsho Men'eki Gakkai Kaishi = Japanese Journal of Clinical Immunology, 38(2), 79-85. https://doi.org/10.2177/jsci.38.79
Sugita S. [Retinal Regeneration With iPS Cells ‒ Clinical Trials for Retinal Degenerative Disorders]. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(2):79-85. PubMed PMID: 26016634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Retinal regeneration with iPS cells ‒ Clinical trials for retinal degenerative disorders]. A1 - Sugita,Sunao, PY - 2015/5/29/entrez PY - 2015/5/29/pubmed PY - 2016/9/20/medline SP - 79 EP - 85 JF - Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology JO - Nihon Rinsho Meneki Gakkai Kaishi VL - 38 IS - 2 N2 - Potential for re-programming cells has become widely accepted as a tool for obtaining transplantation materials. There has been great interest in cell-based therapies, including retinal transplants, because there is a reduced risk of immune rejection. Stem cells have the capacity for self-renewal plus the capacity to generate several differentiated cells. They are derived from many sources including human adult-derived induced pluripotent stem (iPS) cells and have found early application in the context of ocular disease. In results, our established iPS-retinal pigment epithelial (RPE) cells are high-quality RPE cells. iPS cells-derived RPE cells clearly showed polygonal morphology (mostly hexagonal) and contained melanin. Moreover, RPE cells derived from iPS cells had many characteristics of mature RPE cells in vivo, but no characteristics of pluripotent stem cells. Recently, we transplanted RPE cell sheets to treat a patient with wet age-related macular degeneration (September, 2014). In addition, we are now conducting experiments to determine whether allogeneic T cells can recognize iPS-RPE cells from HLA-A, B, DRB1 locus homozygote donors. iPS bank might be useful as allografts in retinal disorders, if the recipient T cells cannot respond to allogeneic RPE cells because of match to some of main HLA antigens. SN - 1349-7413 UR - https://www.unboundmedicine.com/medline/citation/26016634/[Retinal_regeneration_with_iPS_cells_‒_Clinical_trials_for_retinal_degenerative_disorders]_ DB - PRIME DP - Unbound Medicine ER -